NEW HAVEN, Conn., May 7 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that researchers will be presenting two presentations and two posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Helsinki, Finland from May 16-19, 2009.
Independent researchers, Dr. Franciose van Bambeke and Dr. Sandrine Lemaire, both from Universite Catholique de Louvain, will each make oral presentations describing the unique microbiological and pharmacodynamic properties of Rib-X's novel oxazolidinone, radezolid, during a session entitled Pharmacokinetics/Pharmacodynamics: Clinical Relevance, on Saturday, May 16th.
Additionally, Rib-X researchers will be presenting two posters on delafloxacin, one of which discusses the activity and efficacy of delafloxacin in a Phase 2 clinical trial for complicated Skin and Skin Structure Infections. The second poster session details the in vitro activity of delafloxacin against a large, worldwide panel of methicillin-resistant Staphylococcus aureus.
Details on the presentations and abstracts are as follows: Date Time Session Title Location/Poster May 16, 3:06pm - PK/PD: The novel oxazolidinone Lecture Hall 3a 2009 3:18pm Clinical radezolid (RX-1741) Relevance accumulates in THP-1 macrophages: comparative studies with linezolid and azithromycin. May 16, 3:18pm - PK/PD: Radezolid (RX-1741), a Lecture Hall 3a 2009 3:30pm Clinical novel oxazolidinone, is Relev
|SOURCE Rib-X Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved